Biocytogen Forecasts Profit Surge on Overseas Expansion and Industry Recovery in 2025

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) has shared an update.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has issued an inside information announcement of its unaudited estimated financial results for 2025, projecting revenue of RMB1.37 billion to RMB1.39 billion, a year-on-year increase of about 40%, and net profit attributable to shareholders of RMB162.4 million to RMB182.4 million, reflecting a surge of roughly 384% to 444% from 2024. Excluding non-recurring items, net profit is expected to rise by about 357% to 444%, supported by rapid revenue growth from expanding overseas markets, recovery in China’s biopharmaceutical industry, and the company’s high-entry-barrier technologies and lean management, which have sustained high gross margins and boosted operational efficiency; management cautions that the figures are preliminary and unaudited, but notes no material uncertainties currently identified.

The most recent analyst rating on (HK:2315) stock is a Hold with a HK$48.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.

More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a China-based biopharmaceutical company listed in Hong Kong, focused on developing and commercializing innovative biotech solutions. Leveraging high-barrier technologies and an expanding presence in overseas markets alongside a recovering domestic biopharma sector, the group targets sustained growth in revenue and profitability within the competitive pharmaceutical and biotech industry.

Average Trading Volume: 1,492,765

Technical Sentiment Signal: Hold

Current Market Cap: HK$17.06B

See more data about 2315 stock on TipRanks’ Stock Analysis page.